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Abstract
Background: Investigator-initiated clinical studies (IITs) are crucial to generate reliable evidence that answers questions
of day-to-day clinical practice. Many challenges make IITs a complex endeavour, for example, IITs often need to
be multinational in order to recruit a sufficient number of patients. Recent studies highlighted that well-trained
study personnel are a major factor to conduct such complex IITs successfully. As of today, however, no overview
of the European training activities, requirements and career options for clinical study personnel exists.
Methods: To fill this knowledge gap, a survey was performed in all 11 member and observer countries of the European
Clinical Research Infrastructure Network (ECRIN), using a standardised questionnaire. Three rounds of data collection
were performed to maximize completeness and comparability of the received answers. The survey aimed to describe
the landscape of academic training opportunities, to facilitate the exchange of expertise and experience among
countries and to identify new fields of action.
Results: The survey found that training for Good Clinical Practice (GCP) and investigator training is offered in all
but one country. A specific training for study nurses or study coordinators is also either provided or planned in
ten out of eleven countries. A majority of countries train in monitoring and clinical pharmacovigilance and offer
specific training for principal investigators but only few countries also train operators of clinical research organisations
(CRO) or provide training for methodology and quality management systems (QMS). Minimal requirements for study-
specific functions cover GCP in ten countries. Only three countries issued no requirements or recommendations
regarding the continuous training of study personnel. Yet, only four countries developed a national strategy for
training in clinical research and the career options for clinical researchers are still limited in the majority of countries.
Conclusions: There is a substantial and impressive investment in training and education of clinical research in the
individual ECRIN countries. But so far, a systematic approach for (top-down) strategic and overarching considerations
and cross-network exchange is missing. Exchange of available curricula and sets of core competencies between
countries could be a starting point for improving the situation.
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Background
Investigator-initiated clinical studies (IITs) help to answer
questions that clinicians face in their day-to-day practice.
They are initiated and managed in a non-commercial
setting by a researcher/s (individual investigator, academic
institution, a collaborative study group, etc). IITs play a
vital role in the generation of evidence that can eventually
drive policy. A good IIT is one that asks a question that
has scientific merit, has robust research methodology, has
rigorous ethical and scientific governance, a committed
and motivated investigator, institutional support, a fund-
ing agency that recognizes the value of the research and a
team that backs him/her up [1]. However, there are many
challenges posed by an IIT, as has recently been shown
with the example of Portugal. Besides limited funds and
missing local infrastructure, a lack of trained study
personnel is seen as a major hurdle [2, 3]. More and more,
IITs need to be multinational (e.g. in order to recruit
sufficient numbers of patients), which increases their
complexity.
Many important publications have emphasised and
confirmed the importance of training and education to
improve the quality, impact and efficiency of clinical
research in general. The Lancet series on “Research:
increasing value, reducing waste” [4–8] mentions that
training and education are important measures for
increased impact of clinical research results on medical
therapies. The OECD says that support for and facilitation
of the education, training and infrastructure required for
academic clinical trials are key elements of the success of
clinical research [9]. Qualified and experienced staff are
essential at several levels for conducting clinical trials, as
the German Scientific Council states [10].
But what does the European landscape for training in
clinical research look like? The National Scientific Part-
ners of the European Clinical Research Infrastructure
Network (ECRIN) are a major provider of training in
clinical research and well informed on activities in their
own countries. Therefore, a survey in ECRIN member and
observer countries was performed to map the status of
training activities at the national level in the National
Scientific Networks. However, considerable heterogeneity
between the partners with respect to involvement in na-
tional training activities has been reported. ECRIN is a sus-
tainable, non-profit, distributed infrastructure with the legal
status of a European Research Infrastructure Consortium
(ERIC). The vision of ECRIN is to generate scientific evi-
dence with a focus on IITs to optimise medical standards
of care. To this end, ECRIN supports investigators and
(mainly) academic sponsors in the planning and design of
multinational clinical research [11]. ECRIN has nine mem-
ber countries and two observer countries (Table 1).
Scientific partners of ECRIN are national clinical research
networks that are composed of academic clinical research
centres (CRCs) or clinical trial units (CTUs) with a national
coordinating centre (Table 1) [12]. As per ECRIN-ERIC
statutes, the scientific partners must have developed shared
tools, procedures and practices to facilitate multi-centre
studies, have reached a critical mass in competence and
represent the standard in the country [13].
Objectives of the survey:
 To describe the landscape of academic training
opportunities in clinical research as described by the
ECRIN partners
 To enable synergies by facilitating the exchange of
expertise and experience in national training in
clinical research
 To identify new fields of action for ECRIN to
increase the quality and efficiency of multinational
clinical research
In Additional file 1 a longer description of ECRIN is
included.
Table 1 National Clinical Research Networks belonging to ECRIN
Country ECRIN national scientific partner
Czech Republic CZECRIN—Czech Clinical Research Infrastructure Network
France F-CRIN—French Clinical Research Infrastructure Network
Germany KKSN—Network of Coordination Centres for Clinical Studies
Hungary HECRIN—Hungarian Clinical Research Infrastructure Network
Ireland HRB CRCI—Health Research Board, Clinical Research Coordination Ireland
Italy ItaCRIN—Italian Clinical Research Infrastructure Network
Norway NorCRIN—Norwegian Clinical Research Infrastructure
Portugal PtCRIN—Portuguese Clinical Research Infrastructure Network
Slovakia* SLOVACRIN—Slovak Clinical Research Infrastructure Network
Spain SCReN—Spanish Clinical Research Network
Switzerland* SCTO – Swiss Clinical Trial Organisation
*Observer country
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Methods
The survey was initiated in April 2018. A first version of
the questionnaire was sent to the ECRIN members on
20 April 2018. The answers were compiled and pre-
sented at the NC meeting on 14 May 2018. It was
decided to provide a first internal report and to give the
individual countries the opportunity to go back to the
questions and complete/update if needed.
As a consequence, the interim report and an updated
questionnaire with a more standardised answer format
were distributed to the members of the NC on 15 June
2018 with a deadline of 13 July 2018. On 14 August
2018, a reminder was sent to countries which had not
yet provided the filled-in questionnaire. On 4 October
2018 the second round of data collection was completed
and the next version of the report was finalised on 19
October 2018. The information provided was considered
being of high value, but still too heterogenous to be
shared with a broader audience. Therefore, the NC
agreed to perform a third revision of the report, which
was completed in January 2019.
Results
Overview
All members/observers from ECRIN participated in the
survey. Table 2 gives an overview of the answers
received.
GCP training
Specific (basic and advanced) GCP training is provided
by ECRIN members/observers in all but one country.
The training is usually targeted at investigators, study
nurses/coordinators and members of the research team
and normally provided by the local CTU. In Germany it
is provided as an introductory or refresher course.
Standardised curricula are applied in Czech Republic
(network standard), Hungary (accredited course, covered
partly by the Hungarian Society of Pharmacology, with
exams, which is valid for 5 years), Portugal (CLIC Phar-
maTrain [14]/ECRIN [15]), Slovakia and Switzerland
(accredited by swissethics). In Ireland GCP training is
targeted at IMP and medical devices (mandatory). GCP
courses for investigators are mandatory in Germany,
Hungary, Ireland, Norway, Portugal and Switzerland and
are not mandatory in France and Spain, though GCP
must be well known.
In some countries, there is a collaboration with com-
mercial clinical research organisations (CROs) for GCP
training (e.g. Norway, Portugal), some of them with
Transcelerate recognition [16].
Study nurse/coordinator training
Specific study nurse, respectively coordinator training is
provided or planned in ten countries (in preparation in
Slovakia and Norway). In Czech Republic, Germany,
Hungary, Portugal, Spain and Ireland this training is op-
tional; in Italy it is mandatory. The training is provided by
CTUs (Germany, Ireland and Portugal), private com-
panies (Italy and Portugal) or a mixed consortia
(Hungary). Only in Germany is a standardised curriculum
applied. Norway and Switzerland are in the planning
phase for a curriculum.
Investigator training
Ten countries offer investigator training. Mandatory
investigator courses are performed by local CTUs in
Germany, Ireland and Switzerland and by a consortium
in Hungary. A standardised curriculum has been
Table 2 Overview of the training activities for clinical research in each country
Training activity Country
CZE FRA DEU HUN IRL ITA NOR PRT SVK ESP CHE
GCP X X X X X X X X X X
Study nurse/coordinator X X X X X (X) X (X) X X
Investigator X X X X X X X X X X
Monitoring X X X X X X X X
PV/clinical pharmacology X X X X (X) X X
Principal investigator X X X X X X X
CRO operators X X X
Methodology X X X X X
QMS X X X X X
Postgraduate X X X X X X X X
Other X X X X X
X = available, (X) = planned
CZE Czech Republic, FRA France, DEU Germany, HUN Hungary, IRL Ireland, ITA Italy, NOR Norway, PRT Portugal, SVK Slovakia, ESP Spain, CHE Switzerland, GCP Good
Clinical Practice, PV pharmacovigilance, CRO clinical research organization, QMS quality management system
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implemented in Germany by KKSN and Portugal (CLIC
level 1 plus level 2 for principal investigators (PIs) [14]).
In Czech Republic, the training is optional.
Monitoring training
Monitoring training based upon a standardised curricu-
lum is used in Czech Republic (mandatory for CZECRIN
CRAs, provided by CZECRIN or an external agency) and
Germany (optional, provided by CTUs). Monitoring
training is also offered in France, Hungary, Norway,
Portugal (by PTCRIN CTUs or external organizations),
Spain and Switzerland (eight countries in total).
Pharmacovigilance training/training in clinical
pharmacology
Training in clinical pharmacology is implemented in
Germany, Hungary, Portugal and Spain. In Hungary it is
intended for PIs and mandatory for phase 1 trials and
optional for phase 2–3 trials. It is based upon standar-
dised curricula and allows certification. The MD degree
in clinical pharmacology should be regularly enforced
with exams every 5 years. In CZECRIN, mandatory phar-
macovigilance (PV) courses are provided by an external
agency for CZECRIN staff based upon a standardised
curriculum. Norway has had a medical speciality of clin-
ical pharmacology taking 5 years since 1989. Portugal
has a medical specialization with 4 years of training.
Slovakia is planning a PV course for investigators and
study nurses. In Switzerland, a MD can acquire a recog-
nised specialty title in Clinical Pharmacology and Toxi-
cology, duration 5 years.
PI/coordinator training
Seven countries perform PI/ coordinator training. The PI
training offered in Germany and Portugal is optional, based
on a standardised curriculum by KKSN or PTCRIN/
UNAVE (Aveiro University [14]) and provided by the
CTUs (Germany) or by e-learning platform (Portugal). In
addition, there is optional and non-standardised training
for study coordinators. In Switzerland, mandatory PI/spon-
sor-investigator training is available.
Training of CRO operators (staff operating or working for a
CRO)
Italy has comprehensive, mandatory training for CRO
operators for all activities, including monitoring, quality,
GCP, good manufacturing practice (GMP) and PV
(mainly for phase I trials). Germany and Portugal offer
training for CRO operators as well.
Methodological training
In Ireland, a wide range of training in trial methodology
based upon national curricula is provided and performed
nationally through HRB TMRN. Also, Spain, Portugal
(CLIC level 2 [14] and others) and Switzerland offer
such training. France has a specific methodological
training in Parkinson’s disease. In a collaboration
between Harvard Medical School and the Portuguese
government, Portugal has implemented a clinical scholars
research training programme dedicated to medical doc-
tors [17].
Quality management system training
Quality management system (QMS) training is provided
in Czech Republic, France (optional), Portugal (optional),
Germany and Ireland (mandatory and provided nation-
ally through HRB-CRCI).
Postgraduate training
There are several activities with respect to postgraduate
training. In Czech Republic, a mandatory clinical trials
course for PhD students, using a standardised PhD cur-
riculum, is provided by local CZECRIN staff and senior
clinical researchers. Germany has a broad spectrum of
master programmes, including a Master of Clinical Trial
Management (MSc), a “Clinical Evaluation” study
programme, a master of science in “Clinical Research &
Translational Medicine”, a master of science in “Medical
Biometry/Biostatistics” and a master of science in
“Pharmaceutical Medicine”. Ireland [18–22] and Switzerland
[23] also provide different optional postgraduate training
courses in clinical research (MSc courses and other post-
graduate courses, including a specialty title in Pharmaceut-
ical Medicine for MDs and dedicated PhD programmes for
clinical researchers). Portugal has implemented a master in
clinical research management (MEGIC) [24] and has several
PhD and master courses on epidemiology and clinical re-
search. The latter is offered in Norway as well. Postgraduate
courses in Hungary and Slovakia were not further specified.
Table 3 provides complementary information.
Other types of training, general remarks
France offers MD training courses focused on good
practice and technical issues (optional). Ireland offers
two optional training programmes aimed at medical de-
vice development, training and education. In Germany,
an advanced training course for clinical studies with
medical devices is offered (complementary to the investi-
gator training and following a standardised curriculum).
Other specific training activities were reported from
several countries. Germany offers training courses in
medical English for study personnel as well as for people
handling dangerous goods. Hungary offers project-
specific training, HRDOP [34], ERASMUS [35]. France
offers a broad range of specific training courses in e.g.
imaging, European trials, study drug issues, basic infor-
mation for patients (responsible representatives), risk
management, rare diseases, human sample collection,
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Table 3 Career options and academic titles in clinical research
Country Career options and academic titles for clinical research
Czech
Republic
Career options: study nurses, coordinators, researchers, biostatistician, methodologist
Academic titles: none
France Career options: positions with academic sponsors and CTUs, but poor progression in careers, low salaries,
insufficient recognition. Options: clinical research associate (CRA), project manager, data manager
Academic titles: none
General remarks: poor and not specific, no specific training for MDs, technical personnel; no recognition
of clinical research know-how for hospital career
Germany Career options: employment in academic research institutions, pharmaceutical industry, authorities or CROs
Academic titles: [25–32]
MS Clinical Research & Translational Medicine, Universität Leipzig (part time)
MS Clinical Trial Management, Beuth Hochschule für Technik, Berlin (part time)
MS Pharmaceutical Medicine, Universität Duisburg-Essen (part time)
MS Medical Biometry/Biostatistics, Universitäts Heidelberg (part time)
MS Clinical Research, International University Dresden (part time)
MS Clinical Research, Centrial Tübingen, berufsbegleitend
MBA Clinical Research Management, Internationale Hochschule (study at a distance)
BSc Medical Research and Management, Medical School Berlin (full time)
Hungary All four medical schools offer various PhD training programmes in clinical research.
Our aim is that the CTUs could select well-trained staff from the students who have achieved outstanding
results during participation in the HRDOP training courses. The goal is also to increase the number and the
quality of human clinical trials by developing and implementing a co-constructed training curriculum, from
students participating in medical training to the clinical study team
Ireland Career options: careers in clinical research in Ireland are generally funded through programmatic funding or
individual study funding, rather than through core permanent funding, which limits the career pathways for
those involved in clinical research. With the development of the national infrastructure, i.e. Clinical Research
Facilities, respectively. centres and national thematic networks, more secure roles and career paths have developed
but the majority of this infrastructure is also funded through programmatic funding (generally 3-year terms)
rather than core permanent funding, which is problematic in terms of career paths. Career options correspond
to those offered in Spain and there are further options in CRO’s, pharma and medical device companies
Academic titles: see [18–22].
Italy Career options at CROs, private companies, hospital/academic clinical trial centres, no academic titles in clinical
research
Norway No specific career options but, based on acquired competence, positions in research departments/CTUs are
available. In some hospitals part-time functions as research leaders are available at the department level
Academic titles: none
Portugal Career options: study nurse/study coordinator, clinical research assistant/CRA, project manager, auditor/quality
manager, data manager, bio-statistician, clinical investigator
Academic titles:
PhD in Clinical Research and Health services (Faculdade de Medicina, Univ. Porto)
PhD in Experimental and Clinical Pharmacology and Toxicology (Faculdade de Medicina, Univ. Porto)
PhD in Medicine (six Universities in Portugal)
Medical competency in “Pharmaceutical Medicine” (Portuguese Medical Association)
Medical specialist in “Clinical Pharmacology” (Ministry of health)
MSc (Master of Science) in:
• Clinical Research Management (Nova Medical School, Univ. Nova Lisboa)
• Medicines and Health Products: Regulatory and Evaluation (Faculdade de Farmácia, Univ. Lisboa)
• Applied Pharmacology (Faculdade de Farmácia, Univ Coimbra)
• Epidemiology (Faculdade de Medicina, Univ. Lisboa)
• Biostatistics and Bioinformatics applied to health (Escola Superior de Tecnologias da Saúde, Porto)
Slovakia* Career options: clinical study coordinator in hospitals
Academic titles: none
Spain Career options: study nurse, clinical investigator, study coordinator, data entry, CT pharmacist, CTA, CRA, project
manager, clinical trial manager, data manager, bio-statistician, pharmacovigilance, methodologist, quality
management
Academic titles: Biostatistics (University), Clinical Pharmacology—medical specialty (Health Ministry), different
private or university specific courses on monitoring and/or project management
Switzerland*
(see also [23])
Career options: study nurse/study coordinator, clinical research assistant/CRA, project manager, auditor/quality
manager, data manager, bio-statistician, clinical investigator
Academic titles:
PhD in clinical research
Federal physician specialist title “Pharmaceutical Medicine”
MAS (Master of advanced studies):
• MAS in Drug Discovery and Clinical Development
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and data management [36]. Furthermore, a “train the
trainer” program is offered for clinical research [37].
In Spain, besides GCP and methodology, all training is
internal for SCReN members (and mandatory). In
Switzerland, a comprehensive list showing all clinical re-
search training provided by the network is available (see
also [23]).
Minimal requirements for a study specific function (e.g.
CRA, biostatistician)
Minimal requirements for study-specific functions cover
GCP in ten countries: Czech Republic (PI, study team
members), France, Germany (study personnel), Hungary,
Ireland (clinical research staff), Norway (PI), Portugal
(clinical research staff), Slovakia (investigators), Spain
(PI) and Switzerland. Additional requirements have been
reported for phase I units in France and Hungary [38],
for CRO operators in Italy and for PIs and sponsor PIs
in Switzerland.
National requirements for continuous education in clinical
research
Eight countries have national requirements for continu-
ous training. Repeated GCP training is required in Czech
Republic, Germany, Ireland and Spain (commonly every
2 years), in Portugal (every 3 years), Hungary (every 5
years) and Slovakia. Swissethics recommends that after
the initial Training in Research Ethics and GCP has
taken place, the knowledge is maintained by regular re-
search activity, e.g. conducting clinical trials, attending
continuing education related to research or GCP refresher
courses, being exposed to GCP inspections, etc. In Hungary,
participation in yearly educational programmes is highly
advised and in an ongoing project the qualification require-
ments and the duration of their validity will be determined
for the clinical trial team in human clinical studies. In
Germany, refresher courses every 2 years for medical devices
are mandatory. In Spain, in phase 1 trial units, certification
for cardiovascular resuscitation and emergency treatment is
required. No national requirements were reported from
France, Italy and Norway.
Overarching national strategy/roadmap/standards for
training in clinical research
In four countries, an overarching national strategy is in
place or foreseen for training: Germany (GCP training
for investigators and study personnel according to the
curriculum of the Federal Association of Physicians and
ethics committees), Hungary (Committee on Clinical
Pharmacology and Medical ethics of the Medical Re-
search School), Ireland (Health Research Board strategy
for development of the national network and funding of
HRB-CRCI and HRB Trials Methodology Research Net-
work (TMRN)) and Switzerland (Federal Office of Public
Health (FOPH) 2016–20,121 roadmap for building up
the future generation of clinical researchers encompasses
a total of five work packages, the SCTO contributes to
the implementation [39]). In Hungary, the training mate-
rials (curriculum, admission and exclusion criteria)
resulting from the HRDOP project will be presented to
the Medical Research Council (ETT) and the National
Institute of Pharmacy and Nutrition (OGYÉI) as well.
No national strategy has been specified for France, Italy,
Norway, Portugal and Slovakia. In Czech Republic, a
national strategy is prepared within the Working Com-
mittee for Clinical Trials at the Ministry of Health and
for Spain no information is available.
Career options for clinical research per country
In Table 3 career options and academic titles for clinical
research are listed per country.
Career options for clinical research are still limited in
the majority of countries. The same is true for academic
titles, respectively degrees specific for clinical research;
however, new options for masters and diplomas have
been created.
Table 3 Career options and academic titles in clinical research (Continued)
Country Career options and academic titles for clinical research
• Master in Medicines Development
DAS (Diploma of Advanced Studies):
• Diploma in Pharmaceutical Medicine [33]
• DAS Clinical Trial Practice and Management
• DAS (Diploma of advanced studies) Clinical Research
• DAS (Diploma of advanced studies) Management of Clinical Trials
CAS (Certificate of Advanced Studies):
• CAS Clinical Research I–Clinical Trial Planning and Conduct
• CAS Clinical Research II (Advanced Clinical Trial Management)
• CAS Clinical Research Coordinator
• CAS patient oriented Clinical Research
• CAS in Clinical Data Management
• CAS in Clinical Monitoring
• CAS in Clinical Trial Management
*Observer
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Necessity for complementary international training in
clinical research
All countries participating in the survey support the idea
of offering international training in clinical research.
Concrete proposals were made by Czech Republic (MSc
programmes in “Pharmaceutical Medicine”), France (mas-
ter degree for PIs of multinational studies), Germany
(specific management related to international research
projects, e.g. PharmaTrain, where Hungary organised two
courses in pharmaceutical development), Portugal (CLIC
III for sponsor-coordinators and face to face courses
focusing on key topics, e.g. protocol design, H2020), Spain
(international regulatory requirement training, inter-
national clinical trials coordination, VHP and new centra-
lised evaluation of clinical trials under the new regulation
(536/2014) and Switzerland (training for “lead” CTUs to
facilitate multinational trials). E-learning courses would be
of interest for Czech Republic and France. A coordination
role of ECRIN in this area is proposed by Germany,
Hungary, Ireland and Norway. Certification would be an
option for Ireland and Italy (if certification is recognised
at the national level). Slovakia has no suggestions yet.
Discussion
The European countries included all have academic
training opportunities in clinical research, but to differ-
ent extents. The respondents are open to foster the
exchange of expertise and experience in national training
in clinical research as well as for a more active role of
ECRIN to identify new fields of action, increasing the
quality and efficiency of multinational clinical research.
The investment of the national and local networks in
training and education is substantial and impressive. But
so far, building up training and education programmes
is rather a bottom-up process serving current needs.
Furthermore, there are few systematic approaches for
(top-down) strategic and overarching considerations,
active promotion and cross-network exchange. However,
the EU just recently funded an ERASMUS+ project
(CONSCIOUS: Curriculum Development of Human
Clinical Trials for the Next Generation Biomedical
Students). This consortium is led by Hungary in collabor-
ation with France, Ireland, Czech Republic and Portugal
and is intended to tackle skill gaps and mismatches related
to European-level clinical trial professionals [23].
More exchange between National Scientific Networks of
ECRIN member and observer countries may inspire their
national plans, projects and negotiations. The information
may furthermore serve as a benchmark to position, scru-
tinise and further develop their own organisation. The
national view may be challenged and enriched by the
broader European picture. And last but not least, access
to information, documents and expertise should lead to
a mutual benefit for all members, avoiding duplication
of efforts and a waste of taxpayer money. Showing and
promoting the impact and (untapped) potential of a
network of networks may help to support the continu-
ation of national funding. ECRIN and the scientific
partners may also support the European Union (re-
spectively the responsible taskforces) in continuously
harmonising training once the Clinical Trial Regulation
(EU number 536/2014) enters into force.
Curricula for clinical research functions/determination
of core competencies for specific functions (e.g. for uni-
versal functions like (principal) investigator or study
nurse) and a European-wide agreement on curricula and
core competencies could be an aim. As a starting point,
the exchange of available curricula and sets of core com-
petencies could improve professionalism.
Training offered by ECRIN should be distinguished be-
tween “internal training” (for the CTUs and networks) and
“external training” (e.g. for clients like investigators).
Whereas the latter may preferably be offered at the national
or even local level (may be supported by central offers for
multinational, European or international aspects), internal
training at the European level could be of high value.
The national networks are increasingly creating and of-
fering jobs for highly qualified staff. Furthermore, academic
career paths are starting to be offered more systematically
and are officially recognised, resulting in titles (e.g. PhD in
clinical research). This will lead to more professionalism in
clinical research and will attract more young talents.
ECRIN may map and monitor this development and facili-
tate staff exchanges between national networks.
There are some limitations of the survey. Data collection
has been restricted to 11 member and observer countries
of ECRIN and the coordinating units of the National
Scientific Networks. The ECRIN partners served as a
convenient and representative sample. However, we can-
not exclude other training initiatives not known to the
network. As a consequence, the information may not be
complete in all cases and may not be representative for
the European Union. In addition, heterogeneity in the use
of clinical research terms was identified in the survey. As
an example, different countries have a different under-
standing of the profile of a study coordinator. For some
countries this means “coordinating investigator”, for
others it means rather a project manager function or is a
synonym for study nurse. Defining the different profiles in
advance may help to get a more consistent result in the
future. The same is true for academic titles and degrees
(PhD, master, etc.) versus career options (CRA, data man-
ager, etc.). Nevertheless, the survey has been performed in
three rounds with stepwise improvement of the information
and face to face discussions between the survey participants
and thus gives a good overview of the training activities in
the participating countries (see Additional file 2).
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Conclusions
There is a substantial and impressive investment in train-
ing and education of clinical research in the individual
ECRIN countries. But so far, a systematic approach for
(top-down) strategic and overarching considerations and
cross-network exchange is missing. Exchange of available
curricula and sets of core competencies between countries
could be a starting point for improving the situation.
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